Should You Buy CME Group Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, CME Group Inc. (CME) is rated as a strong fundamental performer with a QOC score of 8.9/10. Trading at $275.09, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 1 of 6 CirclFi valuation models project upside for CME Group Inc. (CME) at $275.09 — the model consensus leans bearish, with a Quality Score of 8.9/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for CME Group Inc. (CME) in 2026?
What Is the Bull Case vs the Bear Case for CME Group Inc. (CME)?
| Bull case — $339.09 target (+23.3%) | Bear case — $82.12 target (-70.1%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, CME Group Inc.'s rating of 8.9/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $82.12 (-70.1%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $339.09 (+23.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +93.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: credit quality trends could provide meaningful support for CME Group Inc.'s revenue and margin trajectory in the Financial Data & Stock Exchanges space. | Industry headwind: credit cycle deterioration represents a meaningful risk for CME Group Inc. and its Financial Data & Stock Exchanges peers. |
| The company's $98.9B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does CME Compare to Its Financial Data & Stock Exchanges Peers?
Valuation data pages: FDS · SPGI · CBOE · MCO · BTOG · MORN · MSCI · TRU · DTCX
Which Other Stocks Score Like CME on Quality?
Closest companies to CME’s Quality of Company score of 8.9/10, across all industries.
- FRT — Federal Realty Investment Trust (QOC 8.9) · analysis
- SPSC — SPS Commerce, Inc. (QOC 8.9) · analysis
- WAB — Westinghouse Air Brake Technologies Corporation (QOC 8.9) · analysis
- URBN — Urban Outfitters, Inc. (QOC 8.9) · analysis
- PR — Permian Resources Corporation (QOC 8.9) · analysis
- LIN — Linde plc (QOC 8.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is CME Group Inc. (CME) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on CME Group Inc. at $275.09. 5/6 models flag overvaluation, median fair value sits at $179.07 (-34.9%), and the risk-reward profile appears unfavorable. Quality at 8.9/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. CME Group Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CME Stock?
Should I buy CME stock right now?
Based on CirclFi's multi-model analysis, 1 of 6 models see upside for CME at $275.09. The models are divided, which means the investment case depends heavily on your assumptions about CME Group Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in CME Group Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (313% spread), signaling high uncertainty; general market and sector-specific risks affecting Financial Data & Stock Exchanges companies. Always diversify and consult a financial advisor.
How does CME compare to its competitors?
Among Financial Data & Stock Exchanges peers, CME holds a Quality Score of 8.9/10. Comparable companies include FDS (QOC 9.0), SPGI (QOC 8.8), CBOE (QOC 9.3). The relative ranking helps investors identify whether CME offers better fundamental quality than alternatives in the same sector.
Is CME a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CME's Quality Score of 8.9/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CME at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $82.12 to $339.09. At $275.09, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CME.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad